Soleno Therapeutics Q2 net loss $4.7 mln

Soleno Therapeutics

06/08/2025 21:13

Overview

Soleno Q2 product revenue $32.7 mln, first revenue from VYKAT XR

Company reports Q2 net loss of $4.7 mln despite revenue generation

Raised $230 mln in stock offering post-Q2, boosting cash reserves

Outlook

Soleno expects selling, general and administrative expenses to increase post-VYKAT XR commercialization

Result Drivers

VYKAT XR LAUNCH - Generated $32.7 mln in product revenue following U.S. launch in April 2025

PATIENT STARTS - Received 646 patient start forms and 295 unique prescribers for VYKAT XR

MARKETING EXPENSES - Increased selling, general and administrative expenses due to commercial launch activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.09
Q2 Net Income
-$4.71 mln
Q2 Basic EPS
-$0.09
Q2 Operating Expenses
$39.18 mln
Q2 Operating Income
-$6.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Soleno Therapeutics Inc is $115.00, about 29% above its August 5 closing price of $81.63

Press Release: ID:nGNXbb7WvK

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)